Total Brain Limited announced that the company will license its International Study to Predict Optimized Treatment for Depression research data to Janssen Research & Development, LLC. The company will use Total Brain's iSPOT-D data to support clinical studies and precision drug development efforts to treat depression. This perpetual license agreement is non-exclusive and makes Janssen R&D the third company to license the iSPOT-D data. iSPOT-D is the study of its kind in depression. The study identified objective indicators of treatment response in more than 1,700 depressed individuals using genetics, cognition, brain structure and function imaging, as well as a range of clinical measures, including: Genetics (850,000 SNPs) A battery of cognitive tests Electroencephalogram (EEG) Event related potentials (ERP) Magnetic resonance imaging (MRI) Diffusion tensor imaging (DTI) Functional magnetic resonance imaging (FMRI) Mainstream clinical assessments.